Halt Medical, a healthcare products manufacturer based in Las Vegas, Nevada, announced that it had received approval from healthcare regulators in Mexico for its Accessa System, a device for the treatment of uterine fibroids.
According to a press release by the company, the Acessa system represents a significant shift in traditional treatment methods for uterine fibroids. According to information from the Centers for Disease Control and Prevention, a government group, fibroids are one of the leading causes of hysterectomy procedures.
As of now, the Acessa system is available in the United States, Europe and Canada. It gives physicians the ability to deliver high-energy radiofrequency waves directly to uterine fibroids through a minimally-invasive procedure. In a traditional fibroid surgery, a healthcare provider has to cut through a patient’s healthy tissue to access the tumor. In some cases, traditional surgical techniques for uterine fibroids require the complete removal of a patient’s uterus.
Jeffrey Cohen is the CEO of Halt Medical. In prepared remarks, he said, "Mexico is the second largest market for medical devices in Latin America." He continued, "We are very excited to have the opportunity to expand our market reach to virtually all of North America."